News

ALERT: FDA approves Praluent (alirocumab) to prevent heart attack, stroke and unstable angina requiring hospitalization

April 29, 2019

TARRYTOWN, N.Y. and PARIS, April 26, 2019 /PRNewswire/ —

* Praluent is the first PCSK9 inhibitor that has shown a meaningful reduction in death from any cause

* Praluent treatment effect was observed in patients already receiving other lipid-lowering therapies, including maximally-tolerated statins

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved Praluent^®(alirocumab) to reduce the risk of heart attack, stroke and unstable angina requiring hospitalization in adults with established cardiovascular (CV) disease.

View full press release

Back to News

We believe that good health is the cornerstone of progress. We are firm in our resolve to make exemplary health care accessible and affordable to all, dedicated to lowering the high rate of cardiovascular disease, including stroke, in minority populations and committed to advocacy and diversity. We are guided by ethical principles in all transactions and strive for excellence in our training and skills.

Donate Now